Comparing all five active treatments to the placebo group in 7-day point-prevalence analyses, using an uncorrected p-value of .05, logistic regression analysis indicated that all active treatments produced higher rates of initial cessation and higher 7-day point-prevalence abstinence rates at 1 week, EOT and 6 months post-quit (with the exception of the lozenge at 1 week) relative to placebo (see Tables 2 and 3). The odds ratios at 6-months post-quit were 1.63 for bupropion, 1.76 for lozenge, 1.83 for patch, 1.74 for bupropion + lozenge and 2.34 for patch + lozenge. With the corrected p-value of .0045, only the patch and the two combination therapies were efficacious at 1 week and EOT, and only the patch + lozenge condition was efficacious at 6 months post-quit (see Tables 2 and 3). Using the corrected p-values, all treatments, except the lozenge, significantly increased the rates of initial cessation (not smoking for at least 1 day in the first week post-quit). The same effects were obtained when logistic regression analyses controlled for race, gender and site.
